Cargando…
Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer
BACKGROUND: The number of somatic mutations detectable in circulating tumor DNA (ctDNA) is highly heterogeneous in metastatic colorectal cancer (mCRC). The optimal number of mutations required to assess disease kinetics is relevant and remains poorly understood. OBJECTIVES: To determine whether incr...
Autores principales: | Boutin, Mélina, Topham, James T., Feilotter, Harriet, Kennecke, Hagen F., Couture, Félix, Harb, Mohammed, Kavan, Peter, Berry, Scott, Lim, Howard J., Goffin, John R., Ahmad, Chaudhary, Lott, Anthony, Renouf, Daniel J., Jonker, Derek J., Tu, Dongsheng, O’Callaghan, Chris J., Chen, Eric X., Loree, Jonathan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302520/ https://www.ncbi.nlm.nih.gov/pubmed/37389190 http://dx.doi.org/10.1177/17588359231183682 |
Ejemplares similares
-
Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma
por: Topham, James T., et al.
Publicado: (2023) -
Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?
por: Solar Vasconcelos, Joao Paulo, et al.
Publicado: (2022) -
Circulating DNA in patients undergoing loco-regional treatment of
colorectal cancer metastases: a systematic review and
meta-analysis
por: Callesen, Louise B., et al.
Publicado: (2022) -
Circulating tumour DNA in the evolving treatment landscape of locally advanced rectal cancer: where does it fit in?
por: Piercey, Oliver, et al.
Publicado: (2023) -
Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors –
can we RECIST? Focus on colorectal cancer
por: Spindler, Karen-Lise Garm, et al.
Publicado: (2023)